We advised the representative of the initial purchasers

Davis Polk advised the representative of the initial purchasers in connection with a debut Rule 144A / Regulation S offering by BioMarin Pharmaceutical Inc. of $850 million of its 5.500% senior notes due 2034. BioMarin will use the net proceeds of the notes, together with cash on hand and expected borrowings under a new term loan facility, to finance its acquisition of Amicus Therapeutics, Inc. and repayment of that company’s debt.

Based in San Rafael, California, BioMarin is a leading global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. For over 25 years, BioMarin has been a pioneer in developing therapies to treat rare conditions, addressing unmet medical needs in multiple rare diseases.

The Davis Polk capital markets team included partner Derek Dostal and associates Jakub P. Jozwiak and Sabrina Rodriguez. The finance team included partner David Hahn and associates Lauren Flint and Scott (Xiantao) Wang. Counsel Dustin Plotnick and associate Benjamin Silver provided tax advice. Partner David R. Bauer and associate Gabrielle Mazero provided intellectual property advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post